Roivant Sciences Ltd (ROIV) USD0.0001 A
0.38%- This stock can be held in a
Stocks and Shares ISA
$0.05
(0.40%)$0.05
(0.40%)Company Information
About this company
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Key people
Key facts
- EPICROIV
- LocationUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINBMG762791017
- Market cap$7.72bn
- Employees750
- Shares in issue679.81m
- ExchangeNASDAQ
- IndexS&P 400 Mid Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.